This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luque, J. C.
Right arrow Articles by Stevens, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luque, J. C.
Right arrow Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1452-1455, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1452-1455.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Efficacy of Micafungin Alone or in Combination against Systemic Murine Aspergillosis

Javier Capilla Luque,1,2 Karl V. Clemons,2,3,4* and David A. Stevens2,3,4

University of Rovira i Virgili, Reus, Spain,1 California Institute for Medical Research,2 Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, San Jose, California 95128,3 Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California 943054

Received 9 August 2002/ Returned for modification 17 November 2002/ Accepted 21 January 2003

We tested the efficacy of micafungin (FK) alone or in combination with other antifungals against systemic murine aspergillosis. FK alone at 10 mg/kg of body weight/dose prolonged survival (P = 0.01) and reduced CFU in the brain and kidney. Combination therapy that used suboptimal FK with amphotericin B or itraconazole prolonged survival. Although no survivors were free of infection, no antagonism was seen. Nikkomycin Z with FK showed significantly greater potency (P < 0.01) than either alone.

* Corresponding author. Mailing address: Division of Infectious Diseases, Santa Clara Valley Medical Center, 751 South Bascom Ave., San Jose, CA 95128-2699. Phone: (408) 998-4557. Fax: (408) 998-2723. E-mail: clemons{at}cimr.org.

Antimicrobial Agents and Chemotherapy, April 2003, p. 1452-1455, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1452-1455.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Spreghini, E., Orlando, F., Santinelli, A., Pisa, E., Loretelli, C., Manso, E., Milici, M. E., Scalise, G., Barchiesi, F. (2009). Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53: 4035-4039 [Abstract] [Full Text]  
  • O'Shaughnessy, E. M., Meletiadis, J., Stergiopoulou, T., P. Demchok, J., Walsh, T. J. (2006). Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 58: 1168-1176 [Abstract] [Full Text]  
  • Stevens, D. A., Ichinomiya, M., Koshi, Y., Horiuchi, H. (2006). Escape of Candida from Caspofungin Inhibition at Concentrations above the MIC (Paradoxical Effect) Accomplished by Increased Cell Wall Chitin; Evidence for {beta}-1,6-Glucan Synthesis Inhibition by Caspofungin.. Antimicrob. Agents Chemother. 50: 3160-3161 [Abstract] [Full Text]  
  • Steinbach, W. J., Cramer, R. A. Jr., Perfect, B. Z., Asfaw, Y. G., Sauer, T. C., Najvar, L. K., Kirkpatrick, W. R., Patterson, T. F., Benjamin, D. K. Jr., Heitman, J., Perfect, J. R. (2006). Calcineurin Controls Growth, Morphology, and Pathogenicity in Aspergillus fumigatus.. Eukaryot Cell 5: 1091-1103 [Abstract] [Full Text]  
  • Segal, B. H., Walsh, T. J. (2006). Current Approaches to Diagnosis and Treatment of Invasive Aspergillosis. Am. J. Respir. Crit. Care Med. 173: 707-717 [Abstract] [Full Text]  
  • Dennis, C. G., Greco, W. R., Brun, Y., Youn, R., Slocum, H. K., Bernacki, R. J., Lewis, R., Wiederhold, N., Holland, S. M., Petraitiene, R., Walsh, T. J., Segal, B. H. (2006). Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47phox-/- Mouse Model of Chronic Granulomatous Disease. Antimicrob. Agents Chemother. 50: 422-427 [Abstract] [Full Text]  
  • Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2005). Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis. Antimicrob. Agents Chemother. 49: 4867-4875 [Abstract] [Full Text]  
  • Olson, J. A., Adler-Moore, J. P., Smith, P. J., Proffitt, R. T. (2005). Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin. Antimicrob. Agents Chemother. 49: 4895-4902 [Abstract] [Full Text]  
  • Marine, M., Serena, C., Fernandez-Torres, B., Pastor, F. J., Guarro, J. (2005). Activities of Flucytosine, Fluconazole, Amphotericin B, and Micafungin in a Murine Model of Disseminated Infection by Candida glabrata. Antimicrob. Agents Chemother. 49: 4757-4759 [Abstract] [Full Text]  
  • Serena, C., Fernandez-Torres, B., Pastor, F. J., Trilles, L., Lazera, M. d. S., Nolard, N., Guarro, J. (2005). In Vitro Interactions of Micafungin with Other Antifungal Drugs against Clinical Isolates of Four Species of Cryptococcus. Antimicrob. Agents Chemother. 49: 2994-2996 [Abstract] [Full Text]  
  • Serena, C., Pastor, F. J., Gilgado, F., Mayayo, E., Guarro, J. (2005). Efficacy of Micafungin in Combination with Other Drugs in a Murine Model of Disseminated Trichosporonosis. Antimicrob. Agents Chemother. 49: 497-502 [Abstract] [Full Text]  
  • Martin, C. A. (2005). Invasive Fungal Infections in the Critically Ill Patient. Journal of Pharmacy Practice 18: 9-17 [Abstract]  
  • Cuenca-Estrella, M. (2004). Combinations of antifungal agents in therapy-what value are they?. J Antimicrob Chemother 54: 854-869 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Maracci, M., Fothergill, A. W., Baldassarri, I., Rinaldi, M. G., Scalise, G. (2004). In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata. Antimicrob. Agents Chemother. 48: 3317-3322 [Abstract] [Full Text]  
  • Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
  • Dannaoui, E., Lortholary, O., Dromer, F. (2004). In Vitro Evaluation of Double and Triple Combinations of Antifungal Drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48: 970-978 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»